Tag: Genomic testing
-
SkylineDx Data Underscores Merlin CP-GEP Test’s Superior Melanoma Risk Stratification
New Findings Highlight Merlin CP-GEP Test Performance Fresh data from SkylineDx indicate that the Merlin CP-GEP test offers superior metastatic-risk stratification for melanoma and more accurate prediction of sentinel lymph node biopsy (SLNB) outcomes than rival benchmarks. In a landscape where accurate risk stratification informs crucial treatment decisions, these results position Merlin CP-GEP as a…
-
Genomic Testing for NSCLC: Insights from the AONN+ Conference for Oncology Navigators
Understanding genomic testing in NSCLC Genomic testing for non-small cell lung cancer (NSCLC) has evolved from a optional add-on to a cornerstone of personalized care. At the recent AONN+ conference, a focused session explored how oncology nurses, advanced practitioners, and navigators can effectively use biomarker testing to inform treatment decisions across NSCLC subtypes. The goal…
-
Genomic Testing for NSCLC: Session at AONN+ Conference Delivers Insights for Oncology Navigators
Overview: Why Genomic Testing in NSCLC Matters for Navigators Genomic testing has become a cornerstone of non-small cell lung cancer (NSCLC) management. At the AONN+ conference, a dedicated session offered practical insights for oncology nurses, advanced practitioners, and navigators who guide patients through complex diagnostic and treatment pathways. The session emphasized that understanding which biomarker…
-
Canada’s Largest Cancer Centre to Offer Genomic Testing to All Patients in Five-Year Study
Groundbreaking five-year study to offer genomic testing to all patients In a major advance for personalized cancer care, Canada’s Princess Margaret Cancer Centre in Toronto announced a comprehensive plan to offer genomic testing to every patient treated at the facility over the next five years. The initiative aims to uncover hereditary health risks hidden in…
-
Genomic Testing to Become Standard for Cancer Patients at Canada’s Largest Center in Five-Year Joint U.S. Study
Overview: A landmark genomic testing initiative Canada’s Princess Margaret Cancer Centre in Toronto has announced a bold plan to offer genomic testing to every patient treated at the facility over the next five years. The program, conducted in collaboration with major U.S. hospitals, aims to determine whether hereditary health risks are embedded in patients’ DNA.…
-
Canada’s Princess Margaret to Offer Genomic Testing to All Cancer Patients in Five-Year Joint U.S. Study
Overview: A New Era in Cancer Care Canada’s largest cancer centre is launching a five-year program to offer genomic testing to every patient treated at the Princess Margaret Cancer Centre in Toronto. The initiative, developed in collaboration with major U.S. hospitals, aims to identify hereditary health risks hidden in patients’ DNA and to integrate these…